Background The use of resequencing microarrays for screening multiple, candidate disease loci is a promising alternative to conventional capillary sequencing. We describe the performance of a custom resequencing microarray for mutational analysis of Congenital Myasthenic Syndromes (CMSs), a group of disorders in which the normal process of neuromuscular transmission is impaired. Methodology/Principal Findings Our microarray was designed to assay the exons and flanking intronic regions of 8 genes linked to CMSs. A total of 31 microarrays were hybridized with genomic DNA from either individuals with known CMS mutations or from healthy controls. We estimated an overall microarray call rate of 93.61%, and we found the percentage agreement between the microarray and capillary sequencing techniques to be 99.95%. In addition, our microarray exhibited 100% specificity and 99.99% reproducibility. Finally, the microarray detected 22 out of the 23 known missense mutations, but it failed to detect all 7 known insertion and deletion (indels) mutations, indicating an overall sensitivity of 73.33% and a sensitivity with respect to missense mutations of 95.65%. Conclusions/Significance Overall, our microarray prototype exhibited strong performance and proved highly efficient for screening genes associated with CMSs. Until indels can be efficiently assayed with this technology, however, we recommend using resequencing microarrays for screening CMS mutations after common indels have been first assayed by capillary sequencing.
References
[1]
Engel AG, Sine SM (2005) Current understanding of congenital myasthenic syndromes. Curr Opin Pharmacol 5: 308–321.
[2]
Ohno K, Tsujino A, Brengman JM, Harper CM, Bajzer Z, et al. (2001) Choline acetyltransferase mutations cause myasthenic syndrome associated with episodic apnea in humans. Proc Natl Acad Sci U S A 98: 2017–2022.
[3]
Ohno K, Brengman J, Tsujino A, Engel AG (1998) Human endplate acetylcholinesterase deficiency caused by mutations in the collagen-like tail subunit (COLQ) of the asymmetric enzyme. Proc Natl Acad Sci U S A 95: 9654–9659.
[4]
Engel AG, Ohno K, Sine SM (2003) Congenital myasthenic syndromes: progress over the past decade. Muscle Nerve 27: 4–25.
[5]
Ohno K, Engel AG, Shen XM, Selcen D, Brengman J, et al. (2002) Rapsyn mutations in humans cause endplate acetylcholine-receptor deficiency and myasthenic syndrome. Am J Hum Genet 70: 875–885.
[6]
Chevessier F, Faraut B, Ravel-Chapuis A, Richard P, Gaudon K, et al. (2004) MUSK, a new target for mutations causing congenital myasthenic syndrome. Hum Mol Genet 13: 3229–3240.
[7]
Beeson D, Higuchi O, Palace J, Cossins J, Spearman H, et al. (2006) Dok-7 mutations underlie a neuromuscular junction synaptopathy. Science 313: 1975–1978.
[8]
Webster R, Brydson M, Croxen R, Newsom-Davis J, Vincent A, et al. (2004) Mutation in the AChR ion channel gate underlies a fast channel congenital myasthenic syndrome. Neurology 62: 1090–1096.
[9]
Ohno K, Engel AG (2005) Splicing abnormalities in congenital myasthenic syndromes. Acta Myol 24: 50–54.
[10]
Nichols P, Croxen R, Vincent A, Rutter R, Hutchinson M, et al. (1999) Mutation of the acetylcholine receptor epsilon-subunit promoter in congenital myasthenic syndrome. Ann Neurol 45: 439–443.
[11]
Muller JS, Abicht A, Christen HJ, Stucka R, Schara U, et al. (2004) A newly identified chromosomal microdeletion of the rapsyn gene causes a congenital myasthenic syndrome. Neuromuscul Disord 14: 744–749.
[12]
Muller JS, Stucka R, Neudecker S, Zierz S, Schmidt C, et al. (2005) An intronic base alteration of the CHRNE gene leading to a congenital myasthenic syndrome. Neurology 65: 463–465.
[13]
Beeson D, Hantai D, Lochmuller H, Engel AG (2005) 126th International Workshop: congenital myasthenic syndromes, 24-26 September 2004, Naarden, the Netherlands. Neuromuscul Disord 15: 498–512.
[14]
Mandal MN, Heckenlively JR, Burch T, Chen L, Vasireddy V, et al. (2005) Sequencing arrays for screening multiple genes associated with early-onset human retinal degenerations on a high-throughput platform. Invest Ophthalmol Vis Sci 46: 3355–3362.
[15]
Tengs T, Lee JC, Guillermo Paez J, Zhao X, Laframboise T, et al. (2005) A transforming MET mutation discovered in non-small cell lung cancer using microarray-based resequencing. Cancer Lett 229: 227–233.
[16]
Xu N, Podolsky RH, Chudgar P, Chorich LP, Liu C, et al. (2005) Screening candidate genes for mutations in patients with hypogonadotropic hypogonadism using custom genome resequencing microarrays. Am J Obstet Gynecol 192: 1274–1282.
[17]
Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, et al. (2001) A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409: 928–933.
[18]
Cutler DJ, Zwick ME, Carrasquillo MM, Yohn CT, Tobin KP, et al. (2001) High-throughput variation detection and genotyping using microarrays. Genome Res 11: 1913–1925.
[19]
Huentelman MJ, Craig DW, Shieh AD, Corneveaux JJ, Hu-Lince D, et al. (2005) SNiPer: improved SNP genotype calling for Affymetrix 10K GeneChip microarray data. BMC Genomics 6: 149.
[20]
Karaman MW, Groshen S, Lee CC, Pike BL, Hacia JG (2005) Comparisons of substitution, insertion and deletion probes for resequencing and mutational analysis using oligonucleotide microarrays. Nucl Acids Res 33: e33.
[21]
Hacia JG (1999) Resequencing and mutational analysis using oligonucleotide microarrays. Nat Genet 21: 42–47 (Suppl.).
